Drug intelligence / Profile preview

OHB-301

Development stage: Unknown
Lead developer: Oak Hill Bio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Parenteral

Overview

OHB-301 is a monoclonal antibody targeting the low-affinity immunoglobulin gamma Fc region receptor II-b (CD32B, also known as FcγRIIB). It acts as an antagonist of this inhibitory receptor. The drug is designed to crosslink the activating IgE receptor (FcεRI) with the inhibitory FcγRIIB on immune cells such as basophils and mast cells, thereby downregulating their activity. This mechanism has potential applications in treating autoimmune disorders by modulating immune cell activation. The drug was originally developed by SuppreMol and later licensed to Oak Hill Bio from Takeda. As of early 2025, it is in early phase 1 clinical development for autoimmune disorders[1][2][5].

Targets

FCGR2B (Fc gamma receptor IIB)

Beyond the preview

Go deeper on OHB-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OHB-301.

Explore the full profile